

ROY COOPER • Governor MANDY COHEN, MD, MPH • Secretary MARK T. BENTON • Assistant Secretary for Public Health Division of Public Health

Developed by the North Carolina Division of Public Health, Communicable Disease Branch

Ehrlichiosis Surveillance from 2015-2020

Background

Ehrlichiosis is a general name to describe several bacterial infections caused by *Ehrlichia spp.* including *E. chaffeensis, E. ewingii,* or *E. muris eauclairensis*. Ehrlichiae are transmitted to humans through the bite of an infected tick. In North Carolina, the most common vector of ehrlichiosis is the lone star tick, *Amblyomma americanum*. Like other tickborne illnesses, Ehrlichiosis can be prevented; it is a serious illness that can be fatal if not promptly treated.

Symptomology

Symptoms of ehrlichiosis typically appear within 1—2 weeks following a tick bite. While there are a number of symptoms, the combination of symptoms can vary from person to person. Symptoms may include fever, headache, fatigue, chills, malaise, muscle aches nausea, vomiting, diarrhea, confusion, conjunctivitis (red eyes), and a rash. Rashes can be present in up to 60% of children and less than 30% of adults.

Epidemiology

<u>National</u>

Incidence varies considerably by geographic area. Ehrlichiosis is most frequently reported in the southeastern and south-central US. In 2018, four states accounted for 50% of all reported cases of Ehrlichiosis: Missouri, Arkansas, New York, and Virginia.¹ The number of reported ehrlichiosis cases has increased since it was added to the National Notifiable Conditions list in 1998; the case fatality rate continues to hover around 1% annually. The national average incidence of ehrlichiosis of confirmed and probable cases in 2019 was 0.65 cases per 100,000.²

North Carolina

The number of reported confirmed and probable cases of ehrlichiosis has gradually increased between 2015 and 2020. The highest incidence of ehrlichiosis typically occurs during the months of June and July. The 5-year average incidence rate of ehrlichiosis in North Carolina between 2015—2019 was 0.65 confirmed and probable cases per 100,000 residents, which is comparable to the national average. The incidence rate of ehrlichiosis in North Carolina in 2020 was 1.00 cases per 100,000 (based on 2019 population data). The decline in Ehrlichiosis cases in 2020 may be linked to the large number of events that were closed as "suspect." Suspected events occur when a patient has a positive laboratory test, but no accompanying clinical data can be gathered.

Diagnosis

Diagnosis of ehrlichiosis is often difficult because symptoms vary from patient to patient and are non-specific, making it difficult to distinguish from other illnesses. Serological and Polymerase Chain Reaction (PCR) tests can be used to confirm clinical diagnosis. However, serological tests are often negative during the acute phase of illness; healthcare providers should use their judgement to treat patients empirically based on the symptoms above.

Prevention

Reducing exposure to ticks is the best defense against ehrlichiosis. There are a number of methods that can be used to prevent tickborne illness:

- Wear permethrin treated clothing (0.5%) when exploring the outdoors.
- Use Environmental Protection Agency (EPA) registered insect repellents containing DEET or picaridin to deter ticks.
- Avoid contact with ticks by avoiding wooded and brushy areas with high grasses and leaf litter and walking in the center of trails.
- Check clothing and skin for ticks you may have encountered while outdoors; shower soon after returning indoors.

Case Demographics (Confirmed and Probable)					
	5 Year Avg (2015-19)		2020		
Gender	No. of Cases	% of total	No. of Cases	% of total	
Male	63	61.9%	49	46.6%	
Female	39	38.1%	56	53.4%	

	5 Year Avg (2015-19)		2020	
Race	No. of Cases	% of total	No. of Cases	% of total
White	56.4	60.6%	74	70.5%
Black or African American	10.8	11.6%	12	11.4%
Native Hawaiian or Pac. Islander	o	٥%	0	٥%
Amer. Indian or Alaskan	0	0.0%	0	0.0%
Asian	2	2.1%	1	<1%
Other	3	3.2%	5	4.7%
Unknown	20.8	22.3%	13	12.4%

Hispanic	5 Year Avg (2015-19)		2020	
Ethnicity	No. of Cases	% of total	No. of Cases	% of total
Yes	4	4.70%	4	3.8%
No	57	61.50%	79	75.2%
Unknown	31	33.80%	22	21.0%

25

20

5

0

0-4

5-9

10-19



Geographic Distribution





Cases by Age

30-39

----- 5 Year Avg

40-49

50-59

60-69

70+

20-29

2020

Confirmed and Probable Ehrlichiosis Cases by

Age Range, NC



¹Data are based on a national surveillance data found at: <u>https://www.cdc.gov/ehrlichiosis/stats/index.html</u>

²Data are based on a national surveillance data found at: <u>https://wonder.cdc.gov/nndss/static/2019/annual/2019-table2f.html</u>

³View NC Disease Statistics here: https://public.tableau.com/profile/nc.cdb#!/vizhome/NCD3NorthCarolinaDiseaseDataDashboard/DiseaseMapsandTrends



ROY COOPER • Governor MANDY COHEN, MD, MPH • Secretary MARK T. BENTON • Assistant Secretary for Public Health Division of Public Health

Developed by the North Carolina Division of Public Health, Communicable Disease Branch

Lyme Disease Surveillance Summary from 2015-2020

Background

Lyme disease is a bacterial infection caused by *Borrelia burgdorferi*, and is transmitted to humans and animals through the bite of infected *Ixodes scapularis* (blacklegged) ticks. Symptoms of Lyme disease include fever, headache, fatigue, and a characteristic bull's-eye rash called erythema migrans (EM). If left untreated, infection can spread to the joints, heart, and nervous system. Diagnosis is based on the presence of symptoms, clinical findings (like an EM rash), exposure to ticks, and serological testing. Most cases of Lyme disease are effectively treated with antibiotics.

Symptomology

Early signs of Lyme disease include fever, chills, headache, fatigue, muscle and joint aches, swollen lymph nodes, and EM rash. It is important to note that an EM rash only occurs in 70—80% of patients, and can take up to 30 days to appear. Untreated Lyme disease can cause a variety of symptoms including severe headaches and neck stiffness, additional EM rashes, arthritis with severe joint pain and swelling, particularly in the knees and other large joints, facial palsy and heart conditions associated with Lyme carditis.

Epidemiology

<u>National</u>

Reported cases of Lyme disease are centered in the Northeast and upper Midwest of the United States, with 15 states designated as high incidence states: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, and Wisconsin. The reported average incidence rate of Lyme disease between 2013—2016 was 8.1 **confirmed** cases per 100,000 residents, with incidence rates of the highest states reaching >50 cases per 100,000.¹ The reported national incidence rate in 2019 was 7.1 **confirmed** cases per 100,000 residents.²

North Carolina

In North Carolina, the reported number of confirmed and probable cases of Lyme disease has increased over the past five years. The highest incidence of Lyme disease in 2020 is largely clustered to the northwestern portion of the state, particularly in Ashe, Alleghany, Buncombe, Madison, Mitchell, Surry, Wilkes, and Yancey counties.³ The 5-year reported average incidence rate of Lyme disease in North Carolina between 2015—2019 was 2.67 **confirmed and probable** cases per 100,000 residents, which is significantly lower than the national average. The estimated incidence of Lyme disease in 2020 was 2.59 **confirmed and probable** cases per 100,000 residents (2019 population data). The decline in Lyme cases in 2020 may be linked to the large number of events that were closed as "suspect." Suspected events occur when a patient has a positive laboratory test, but no accompanying clinical data can be gathered.

Diagnosis

Lyme disease can be physician diagnosed based on the symptoms outlined above, a history of tick exposure and serological testing. Serological tests are effective when used correctly. A positive two-tier test, defined as a positive or equivocal enzyme immunoassay (EIA) or immunofluorescent assay (IFA) followed by a positive Immunoglobulin M^1 (IgM) or Immunoglobulin G² (IgG) western immunoblot (WB) can help to determine active infection. Lab tests are not recommended for patients who do not have symptoms of typical Lyme disease.

Prevention

Reducing exposure to ticks is the best defense against Lyme disease. There are a number of methods that can be used to prevent tickborne illness:

- Wear permethrin treated clothing (0.5%) when exploring the outdoors.
- Use EPA registered insect repellents containing DEET or picaridin to deter ticks.
- Avoid ticks in wooded/brushy areas with high grasses and leaf litter by walking in the center of trails.
- Check clothing and skin for ticks you may have encountered while outdoors; shower soon after returning indoors.

Case Demographics (Confirmed and Probable)					
	5 Year Avg (2015-19)		2020		
Sex	No. of Cases	% of total	No. of Cases	% of total	
Male	134	48.7%	130	47.8%	
Female	141	51.3%	142	52.2%	

	5 Year Avg (2015-19)		2020	
Race	No. of Cases	% of total	No. of Cases	% of total
White	133	52.0%	165	60.7%
Black or African Amer.	9	3.5%	5	1.8%
Asian or Pac. Islander	1	0.4%	2	0.7%
Amer. Indian or Alaskan	0	0.0%	0	0.0%
Other	2	0.8%	2	0.7%
Unknown	111	43.4%	98	36.0%

5 Year Avg (2015-19) 2020 Hispanic Ethnicity No. of Cases % of total No. of Cases % of total Yes 2.04% 1.5% 5 4 No 50.19% 56.3% 133 153 Unknown 127 47.92% 115 42.3%

50

40

30

20

10

0

0-4

5-9

10-19







Geographic Distribution





Cases by Age

30-39

---- 5 Year Avg

40-49

50-59

60-69

70+

20-29

2020

Confirmed and Probable Lyme diseases cases by Month of Illness Onset, NC



¹These data are based on a national surveillance data found at: <u>https://www.cdc.gov/mmwr/volumes/64/wr/mm6453a1.htm?s_cid=mm6453a1_w</u>

²CDC Lyme Disease Data Tables: https://www.cdc.gov/lyme/stats/tables.html

³CDC Case Definition for Lyme Disease: <u>https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2017/</u>

View NC Disease Statistics here: https://public.tableau.com/profile/nc.cdb#!/vizhome/NCD3NorthCarolinaDiseaseDataDashboard/DiseaseMapsandTrends



ROY COOPER • Governor MANDY COHEN, MD, MPH • Secretary MARK T. BENTON • Assistant Secretary for Public Health Division of Public Health

Developed by the North Carolina Division of Public Health, Communicable Disease Branch

Spotted Fever Group Rickettsiosis Surveillance Summary from 2015-2020

Background

Spotted fever group rickettsioses (SFGR), including Rocky Mountain spotted fever, are a group of bacterial infections caused by *Rickettsia spp.* including *R. rickettsii* and *R. parkeri, among others*. Spotted fevers are transmitted to humans through the bite of an infected tick. In North Carolina the most common vectors of spotted fevers include the American dog tick, *Dermacentor variabilis,* the Rocky Mountain wood tick, *D. andersoni,* and the Lone star tick, *Amblyomma americanum*. The brown dog tick, *Rhipicephalus sanguineus* has been implicated in transmission in other parts of the US. If left untreated, illness can become serious, even leading to death.

Symptomology

Early signs of SFGR are non-specific, including fever and headache. Symptoms may appear 3–12 days following a tick bite. Other signs and symptoms can include nausea, vomiting, stomach pain, muscle pain, lack of appetite, and rash (may be present or absent). Rash is a common sign among those infected with *R. rickettsii*, the causative agent of Rocky Mountain spotted fever (RMSF), and usually develops 2-4 days following fever onset. Rashes can look like red splotches or pinpoint dots.

Epidemiology

<u>National</u>

Incidence varies considerably by geographic area. Between 2008-2012, 63% of reported SFGR cases originated from five states: Arkansas, Missouri, North Carolina, Oklahoma, and Tennessee¹. Thousands of cases of SFGR occur every year, but it is unknown how any cases are RMSF. Case fatality rates vary annually, but have decreased overall from 28% in 1944 to < 1% in 2001. The national average incidence of **confirmed and probable** SFGR cases in 2019 was 1.59 cases per 100,000.²

North Carolina

The number of confirmed and probable cases of spotted fever rickettsiosis decreased significantly in North Carolina in 2020. In January 2020, the case definition of SFGR was amended to require an elevated IgG antibody titer of >1:128 within 60 days of illness onset³, which resulted in a sharp decrease in SFGR cases nationwide. The decline in SFGR cases in 2020 may also be linked to the large number of events that were closed as "suspect." Suspected events occur when a patient has a positive laboratory test, but no accompanying clinical data can be gathered. The 5-year average incidence rate of SFGR in North Carolina between 2015—2019 was 5.15 **confirmed and probable** cases per 100,000 residents, which is higher than the national average². The incidence of **confirmed and probable** SFGR cases in North Carolina in 2020 was 1.81 cases per 100,000 residents (using 2019 population data).

Diagnosis

Delay in diagnosis and treatment is the most important factor associated with poor outcomes, and early treatment based on clinical impression is the best way to prevent RMSF progression. Both acute and convalescent serum specimens are needed to confirm the rickettsial infection. Serological tests are often negative during the acute phase of illness, however, physicians may diagnose patients based on the symptoms outlined above.

Prevention

Reducing exposure to ticks is the best defense against SFGR. There are a number of methods that can be used to prevent tickborne illness:

- Wear permethrin treated clothing (0.5%) when exploring the outdoors.
- Use EPA registered insect repellents containing DEET or picaridin to deter ticks.
- Avoid ticks in wooded/brushy areas with high grasses and leaf litter by walking in the center of trails.
- Check clothing and skin for ticks you may have encountered while outdoors; shower soon after returning indoors.

Case Demographics					
	5 Year Avg (2015-19)		2020		
Sex	No. of Cases	% of total	No. of Cases	% of total	
Male	360	68.2%	114	60%	
Female	168	31.8%	76	40%	

	5 Year Avg (2015-19)		2020	
Race	No. of Cases	% of total	No. of Cases	% of total
White	293	56.3%	127	66.8%
Black or African Amer.	31.2	6.0%	13	6.8%
Native Hawaiian or Pacific Islander	0.2	0.0%	о	0.0%
Amer. Indian or Alaskan	1	0.2%	0	0.0%
Asian	2	0.4%	2	1.1%
Other	7.2	1.4%	6	3.2%
Unknown	186	35.7%	42	22.1%
Hispanic	5 Year Avg	(2015-19)	202	20

Hispanic	5 Year Av	g (2015-19)	2020	
Ethnicity	No. of Cases	% of total	No. of Cases	% of total
Yes	15	3.0%	5	2.6%
No	277	55.6%	120	63.2%
Unknown	206	41.4%	65	34.2%



Confirmed and Probable Spotted Fever Group Rickettsiosis by Age Range, NC



Confirmed and Probable Incidence of Spotted Fever Group Rickettsiosis Cases by County of Residence, NC, 2020



Confirmed and Probable Spotted Fever Group Rickettsiosis cases by Month of Illness Onset, NC



¹ Rocky Mountain Spotted Fever Facts: <u>https://www.cdc.gov/ticks/tickbornediseases/rmsf.html</u>

²Data are based on a national surveillance data found at: <u>https://wonder.cdc.gov/nndss/static/2019/annual/2019-table2p-H.pdf</u>

³CDC Spotted Fever Group Rickettsiosis Case Definition: <u>https://wwwn.cdc.gov/nndss/conditions/spotted-fever-rickettsiosis/case-definition/2020/</u>